AI assistant
Sending…
Jazz Pharmaceuticals plc — Director's Dealing 2021
May 7, 2021
30751_dirs_2021-05-07_930dddb7-4f36-4489-81a1-66e411225a8b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2021-05-05
Reporting Person: Tovey Christopher J. (EVP COO & Managing Dir EUR/INT)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-05 | Ordinary Shares | A | 9091 | $0.0 | Acquired | 9116 | Direct |
Footnotes
F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of May 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
More from Jazz Pharmaceuticals plc
Regulatory Filings
2026
May 29
Annual Report
2026
Apr 24
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2